Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hartman

Showing results (251-260 of 272) with videos related to

Pageof 28
Sort By:
Chemistry & Biology|September 17, 2013
Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cellsJared J Barrott, Philip F Hughes, Takuya Osada, et al.
Oncogene|May 10, 2016
The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironmentJ Turpin, C Ling, E J Crosby, et al.
Human Vaccines & Immunotherapeutics|February 8, 2024
Vaccines targeting <i>ESR1</i> activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancerGabrielle P Dailey, Christopher A Rabiola, Gangjun Lei, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 27, 2026
Enhanced Efficacy of a Next-Generation EEEV Self-Replicating RNA Platform for Combination Cancer ImmunotherapiesShigeki J Miyake-Stoner, Christian J Maine, Annie C Chou, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicityZachary C Hartman, Junping Wei, Takuya Osada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational StudyErika J Crosby, William Gwin, Kimberly Blackwell, et al.
Nature Communications|April 2, 2025
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)Li-Chung Tsao, John S Wang, Xingru Ma, et al.
JCI Insight|November 6, 2019
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosisLi-Chung Tsao, Erika J Crosby, Timothy N Trotter, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2021
Adoption of community monitoring improves common pool resource management across contextsTara Slough, Daniel Rubenson, Ro'ee Levy, et al.
Pageof 28

Showing results (251-260 of 272) with videos related to

Sort By:
Pageof 28
Chemistry & Biology|September 17, 2013
Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cellsJared J Barrott, Philip F Hughes, Takuya Osada, et al.
Oncogene|May 10, 2016
The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironmentJ Turpin, C Ling, E J Crosby, et al.
Human Vaccines & Immunotherapeutics|February 8, 2024
Vaccines targeting <i>ESR1</i> activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancerGabrielle P Dailey, Christopher A Rabiola, Gangjun Lei, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 27, 2026
Enhanced Efficacy of a Next-Generation EEEV Self-Replicating RNA Platform for Combination Cancer ImmunotherapiesShigeki J Miyake-Stoner, Christian J Maine, Annie C Chou, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicityZachary C Hartman, Junping Wei, Takuya Osada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational StudyErika J Crosby, William Gwin, Kimberly Blackwell, et al.
Nature Communications|April 2, 2025
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)Li-Chung Tsao, John S Wang, Xingru Ma, et al.
JCI Insight|November 6, 2019
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosisLi-Chung Tsao, Erika J Crosby, Timothy N Trotter, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2021
Adoption of community monitoring improves common pool resource management across contextsTara Slough, Daniel Rubenson, Ro'ee Levy, et al.
Pageof 28